13 results match your criteria: "The First People's Hospital of Zigong City[Affiliation]"
Front Med (Lausanne)
October 2023
Department of Medical Quality Control, The First People's Hospital of Zigong City, Zigong, China.
Front Med (Lausanne)
September 2023
Department of Medical Quality Control, The First People's Hospital of Zigong City, Zigong, China.
Background And Aims: Heart failure (HF) is a significant cause of in-hospital mortality, especially for the elderly admitted to intensive care units (ICUs). This study aimed to develop a web-based calculator to predict 30-day in-hospital mortality for elderly patients with HF in the ICU and found a relationship between risk factors and the predicted probability of death.
Methods And Results: Data ( = 4450) from the MIMIC-III/IV database were used for model training and internal testing.
Front Endocrinol (Lausanne)
August 2023
Department of Medical Quality Control, The First People's Hospital of Zigong City, Zigong, China.
Background: Liver resection (LR) and local tumor destruction (LTD) are effective treatments, but not commonly recommended for patients with intermediate/advanced hepatocellular carcinoma (HCC). This study aimed to explore whether LR/LTD could improve overall survival (OS) of these patients, and to identify the patients who will most likely benefit from LR/LTD.
Methods: Data of patients with intermediate/advanced HCC between 2001 and 2018 were extracted from Surveillance, Epidemiology, and End Results database.
World J Surg Oncol
April 2023
Department of Respiratory, The First People's Hospital of Zigong City, No.42, Shangyihao Road, Ziliujing District, Zigong City, 643000, Sichuan, China.
Background: RNA-binding motif protein 14 (RBM14) is upregulated in a variety of tumors. However, the expression and biological role of RBM14 in lung cancer remain unclear.
Methods: Chromatin immunoprecipitation and PCR were carried out to measure the levels of sedimentary YY1, EP300, H3K9ac, and H3K27ac in the RBM14 promoter.
Cancer Invest
February 2023
Respiratory Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P. R. China.
Objective: To fully investigate the efficacy and safety of bevacizumab for glioblastoma.
Methods: Databases were searched for phase II/III randomized controlled trials treated with bevacizumab.
Results: Bevacizumab significantly improved the PFS in glioblastoma patients, but did not prolong OS.
Tissue Cell
February 2023
Department of Respiratory, The first People's Hospital of Zigong City, Zigong City 643000, Sichuan, China. Electronic address:
Copper chaperone for superoxide dismutase (CCS) is abnormally expressed in various human malignancies. However, the function and mechanism of CCS in lung cancer progression remain unclear. In the current study, CCS protein and mRNA levels were found to be increased in lung adenocarcinoma (LUAD) tissue and cell lines.
View Article and Find Full Text PDFFront Public Health
October 2022
Department of Medical Quality Control, The First People's Hospital of Zigong City, Zigong, China.
Background: Comprehensive studies on the prognosis of solitary bone plasmacytoma (SPB) are lacking, especially in elderly patients with SPB. This study aims to establish a novel nomogram and risk stratification system to predict the overall survival (OS) of elderly patients with SPB.
Methods: The data of elderly patients with SPB from 2000 to 2017 were identified in the SEER database.
Nutr Cancer
August 2022
Emergency Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Pancreatic cancer (PC) is one of the most common malignant tumors with a poor prognosis and high mortality. Surgical resection is the most effective treatment for PC; however, only a minority of patients have resectable tumors. Chemotherapy is the primary treatment for PC.
View Article and Find Full Text PDFFundam Clin Pharmacol
August 2022
Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Aconitum alkaloids are considered to be the characteristic bioactive ingredients of Aconitum species, which are widely applied to the treatment of diverse diseases, and aconitine (AC) is found in most Aconitum plants. Research evidence shows that low-dose AC has a good therapeutic potential in heart failure, myocardial infarction, neuroinflammatory diseases, rheumatic diseases, and tumors, which has become one of the hotspots in global research in recent years. However, the cardiotoxicity and neurotoxicity of AC have also attracted extensive attention.
View Article and Find Full Text PDFJ Chemother
November 2022
Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
We conducted a meta-analysis to systematically review the efficacy and safety of pembrolizumab for advanced NSCLC. Databases were searched for randomized controlled trials (RCTs) treated with pembrolizumab till July 2021. Seven RCTs and 3988 patients were included.
View Article and Find Full Text PDFCell Biol Int
October 2021
Department of Respiratory, The First People's Hospital of Zigong City, Zigong, Sichuan, China.
Lung adenocarcinoma (LUAD) is a deadly disease with a hallmark of aberrant metabolism. TEA domain 4 (TEAD4) is involved in the progression of several forms of cancer including LUAD. However, the role of TEAD4 in LUAD glucose metabolism is rarely reported as well as its potential mechanisms.
View Article and Find Full Text PDFHistol Histopathol
August 2021
Department of Respiratory, The First People's Hospital of Zigong City, Zigong, China.
PHD finger protein 8 (PHF8), serving as a histone demethylase, is upregulated in some types of malignant tumors. The role of PHF8 in non-small-cancer lung carcinoma (NSCLC) remains unclear. This study aims to verify the effect of PHF8 in NSCLC and its molecular mechanism.
View Article and Find Full Text PDFZhongguo Zhong Xi Yi Jie He Za Zhi
July 2008
Objective: To observe the effect of sodium ferulate on the hemodynamics of hepatic cirrhosis patients.
Methods: Eighty-two hepatic cirrhosis patients were randomly assigned to two groups, the 27 patients in the control group were treated by conventional liver protecting therapy, and the 55 patients in the treated group were treated with sodium ferulate besides the conventional therapy. The therapeutic course for both groups was two weeks.